3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
7
Neurofibromatosis 1
6
Neoplasm Metastasis
6
Solid Tumours
5
Neoplasms
5
Melanoma
5
Neurofibroma, Plexiform
4
Lung Neoplasms
3
Colorectal Neoplasms
3
Breast Neoplasms
2
Biliary Tract Neoplasms
2
Uveal Melanoma
1
Solid Tumors
1
Renal Insufficiency
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Muscle Invasive Bladder Cancer
1
Locally Advanced or Metastatic Solid Tumors
1
Kidney Neoplasms
1
Healthy Volunteers Pharmacokinetic Study
1
Disease Progression
1
Differentiated Thyroid Cancer
1
Colonic Neoplasms
1
Advanced Non Small Cell Lung Cancer
1
Advanced Cancer
1
Interventions
pembrolizumab
180
Cisplatin
44
Paclitaxel
41
Carboplatin
41
lenvatinib
31
Docetaxel
22
Pemetrexed
20
Fluorouracil
19
Capecitabine
16
Gemcitabine
15
Saline Solution
13
Oxaliplatin
13
Albumin-Bound Paclitaxel
10
epacadostat
9
130-nm albumin-bound paclitaxel
9
Leucovorin
8
Cetuximab
8
olaparib
7
Irinotecan
7
Bevacizumab
7
Etoposide
6
belzutifan
5
Dexamethasone
5
enzalutamide
4
trifluridine tipiracil drug combination
3
regorafenib
3
patritumab deruxtecan
3
enfortumab vedotin
3
durvalumab
3
Surgical Procedures, Operative
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
AZD 6244
×
Clear all
NCT03833427
2024-11-07
MK-5618-001
Merck Sharp & Dohme LLC
Phase 1
Terminated
32 enrolled
17 charts